News

AgroSpheres Novel Encapsulation Platform Now Listed by Organic Materials Review Institute (OMRI) for Use in Organic Crop Production

AgroSpheres, Inc., an agricultural biobased solutions developer, is pleased to announce that its proprietary encapsulation technology, AgroSpheres® Microbially-Derived Minicells (also known as the AgriCell), was recently reviewed by the Organic Materials Review Institute (OMRI), which has determined that it meets the criteria for use under the USDA National Organic Program (NOP). AgroSpheres® Microbially-Derived Minicells is now listed in OMRI’s Generic Material Listing for use as an inert ingredient in organic crop pest, weed, and disease control. This product is currently pending review and approval by US EPA. Once that approval is granted, it will be available for use in pesticide products for use in organic and conventional crop production.

OMRI’s mission is to support the growth and trust of the global organic community through expert, independent and transparent verification of input materials, and through education and technical assistance. OMRI provided an independent review of the AgriCell encapsulation technology and concluded that the AgriCell met the very high standards that NOP has created for the organic industry. This significant milestone marks a major step forward in advancing environmentally friendly and efficient agricultural practices.

“Obtaining OMRI listed status demonstrates that AgroSpheres’ encapsulation technology complies with the rigorous standards set by NOP for organic production, providing farmers with a trusted and reliable solution to enhance crop yields while maintaining the integrity of their organic operations,” said Payam Pourtaheri, Chief Executive Officer for AgroSpheres.

Emily Pelton, who represents the Virginia Wine Board on the National Grape Research Alliance and is the founder of the Virginia Wine Research exchange, said: “The Wine Board are proud to be early supporters of the AgroSpheres team because we are always on the lookout for more environmentally friendly ways of doing things and this is what AgroSpheres is all about. We are examining everything we can to avoid using toxic materials for disease management, from good vineyard management practices to breeding disease resistant grape varieties. Sadly, this is not easy, and we have fewer tools for organic production than we would like. Hence, we are very excited that AgroSpheres is going to bring a new tool to the toolbox to help fight grape vine diseases that are good for the environment.”

The encapsulated products will be sold through various distributors after product approvals.

To see the OMRI Listed® certificate for AgroSpheres® Microbially-Derived Minicells, click here.

Recent News

05/22/2026

BIO Statement on Veto of Prescription Drug Affordability Boards (PDAB) in VirginiaPatrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription Drug Affordability Board (PDAB) and imposed arbitrary price controls in Virginia. The Governor’s action recognized an important point: even well-intentioned healthcare policies must be carefully designed to avoid unintended consequences for patients, providers, employers, and Virginia’s innovation economy. “BIO is proud to represent biotechnology companies developing the next generation of life-changing medicines, including many in the Commonwealth. We believe policymakers play a critically important role in helping advance both patient access to treatments and the continued growth of the life sciences sector. “We look forward to working with the Governor’s Administration, the General Assembly, Virginia Bio and other stakeholders to advance practical, patient-centered policy solutions that improve affordability while preserving access to care and the innovation ecosystem patients depend on.”

Patrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription

05/21/2026

Virginia Bio Applauds Governor Spanberger’s Veto of SB 271 and HB 483

The Virginia Biotechnology Association (Virginia Bio) today expressed strong support for Governor Abigail Spanberger’s decision to veto Senate Bill 271 and House Bill 483, legislation that would have established a Prescription Drug Affordability Advisory Panel (PDAAP) in the Commonwealth. Virginia Bio and the Virginia Chamber of Commerce sent a joint letter to Governor Spanberger commending

05/21/2026

New Global Clinical Society to Bring Focused Ultrasound Into Mainstream Medicine

The Focused Ultrasound Foundation today announced the launch of the International Focused Ultrasound Society (IFUS), a new organization dedicated to advancing clinical practice and accelerating adoption of focused ultrasound – a revolutionary, noninvasive therapeutic technology. Established as a program of the Focused Ultrasound Foundation, IFUS aggregates and expands the Foundation’s activities related to clinical implementation